Breast Cancer Clinical Trial
Official title:
The Effect of Health Belief Model-based Education Given Through Whatsapp Application on Health Beliefs Regarding Mammography and Re-mammography
Verified date | February 2024 |
Source | Mus Alparlan University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
It is known that the healing process of breast cancer is accelerated thanks to the early diagnosis and effective treatment. Mammography screening is an important diagnostic method in the early diagnosis of breast cancer. It is thought that the education to be given according to the Health Belief Model will make important contributions to developing a positive attitude in breast cancer screenings and regular mammography.
Status | Not yet recruiting |
Enrollment | 134 |
Est. completion date | August 10, 2024 |
Est. primary completion date | April 2, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 40 Years to 69 Years |
Eligibility | Inclusion Criteria: - Be between the ages of 40-69, - Be woman, - Not having been diagnosed with breast cancer, - Not to be pregnant, lactating or puerperal, - Absence of a mental illness - At least 2 years have passed since the last mammogram, - Being able to use the WhatsApp application Exclusion Criteria: - Having had problems with breast cancer before, - Having a mammogram at regular intervals, - Having had breast-conserving surgery for any purpose. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Kemal Yaran |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pre-test evaluation | The Health Belief Model Scale for Breast Cancer Screening and the Mammography Self-Efficacy Scale will be administered to all women in the experimental and control groups for pre-test purposes. There is no overall total score of the Health Belief Model Scale on Breast Cancer Screenings. Each sub-dimension's own total score is evaluated. The scale is a Likert type scale scored from 1 to 5. The scoring of the scale ranges from 1 point for "strongly disagree" to 5 points for "strongly agree". Increasing scores obtained from sub-dimensions indicate that the perception of that sub-dimension is high. Mammography Self-Efficacy Scale has ten items and five-point Likert type. The scale answers "strongly disagree" are evaluated as 1 point, "disagree" as 2 points, "undecided" as 3 points, "agree" as 4 points and "strongly agree" as 5 points. A higher score for each dimension indicates a higher probability of having a mammogram. | Three month | |
Primary | Posttest evaluation | Training presentations will be sent to the experimental group in the first 6 weeks and training videos will be sent in the last 2 weeks. A total of 8 weeks of intervention will be implemented. Training content will be sent via WhatsApp application once a week. No intervention will be made to the control group by the researchers during this period. Those in the control group will be invited to KETEM to have a mammogram. Three months after the training is completed, the Health Belief Model Scale for Breast Cancer Screening and the Mammography Self-Efficacy Scale will be administered to both groups for posttest purposes. | Six month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |